SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Milei Threatens Falkland Oil Firms With Sanctions 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
(4) - EconoTimes)
Add as a preferred source on Google
CAMBRIDGE, Mass., Feb. 28, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on February 28, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to ten individuals hired by Sarepta in February 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 76,200 shares of Sarepta's common stock. The options have an exercise price of $62.77 per share, which is equal to the closing price of Sarepta's common stock on February 28, 2018. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
